STOCK TITAN

Oncocyte Corporation - OCX STOCK NEWS

Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.

Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.

Oncocyte’s flagship products include:

  • DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
  • DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
  • VitaGraft™: A blood-based solid organ transplantation monitoring test.
  • GraftAssure™: A research-use-only monitoring test for solid organ transplantation.

The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.

Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.

Rhea-AI Summary
Oncocyte (OCX) announces a private placement of common stock and pre-funded warrants, totaling 5,420,275 shares, at a purchase price of $2.9164 per share, aiming to raise capital through securities purchase agreements. The private placement is priced 'at-the-market' and is anticipated to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
none
-
Rhea-AI Summary
Oncocyte (OCX) announces a partnership with Bio-Rad Laboratories (BIO) for the commercialization of GraftAssure™ assay, powered by Droplet Digital PCR. The agreement grants Bio-Rad global exclusivity in transplant monitoring commercialization, with an equity investment option upon FDA clearance. The new product is set to launch in Q2 2024 in the US and EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
none
-
Rhea-AI Summary
Oncocyte (OCX) will release its Q4 and full-year 2023 financial results on April 12, 2024. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
Rhea-AI Summary
Oncocyte Corporation (OCX) CEO Josh Riggs will present a corporate overview at the Sequire Investor Summit 2024 in San Juan, Puerto Rico. The conference is scheduled for January 23-25, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
conferences
-
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX) has initiated the FDA single-site process for its VitaGraft transplant assays, positioning the company within the recent proposed rule from the FDA that seeks to oversee Lab Developed Tests (LDTs). The move is expected to create a significant competitive advantage for the company in the multi-billion-dollar transplant testing market and drive adoption beyond the current 25-30%. The company also received a positive coverage decision from MolDX for its Kidney indication, expected to launch commercially in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX) reported positive coverage for VitaGraft Kidney, expecting commercial revenue in 1H 2024. Cash burn declined to $3.6 million, with $14.2 million in cash, equivalents, and securities as of September 30, 2023. Third quarter 2023 financial results showed a net operating loss of $6.5 million, primarily due to increased R&D expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.71%
Tags
Rhea-AI Summary
Oncocyte Corporation, a precision diagnostics company, will host a conference call and webcast on November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET to discuss its third quarter financial results and recent highlights. Interested parties can access the call via telephone or the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
-
Rhea-AI Summary
Oncocyte's VitaGraft assay detects transplant rejection 10 months sooner than standard protocols, according to a clinical trial. Positive coverage determination received for VitaGraft Kidney. Commercialization expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary
Oncocyte Corporation to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Oncocyte Corporation receives positive coverage decision for VitaGraft Kidney diagnostic test, expects initial revenue in Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
none

FAQ

What is the current stock price of Oncocyte Corporation (OCX)?

The current stock price of Oncocyte Corporation (OCX) is $2.03 as of January 24, 2025.

What is the market cap of Oncocyte Corporation (OCX)?

The market cap of Oncocyte Corporation (OCX) is approximately 34.9M.

What does Oncocyte Corporation specialize in?

Oncocyte Corporation focuses on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics for the early detection of cancer.

What types of cancer does Oncocyte's diagnostics target?

Oncocyte's diagnostics target lung, breast, and bladder cancers.

What are some of Oncocyte's key products?

Key products include DetermaIO™, DetermaCNI™, VitaGraft™, and GraftAssure™.

How does Oncocyte's DetermaIO™ test work?

DetermaIO™ is a gene expression test that evaluates the tumor microenvironment to predict response to immunotherapies.

What recent achievements has Oncocyte made?

In 2023, Oncocyte achieved reimbursement for VitaGraft™ Kidney, manufactured the first lots of GraftAssure RUO, and entered a partnership with Bio-Rad Laboratories.

Who are some of Oncocyte's partners?

Oncocyte has a key partnership with Bio-Rad Laboratories for the commercialization of GraftAssure and the development of VitaGraft Kidney IVD.

What is the purpose of Oncocyte's VitaGraft™ test?

VitaGraft™ is a blood-based test used for monitoring solid organ transplantation.

What is GraftAssure™ used for?

GraftAssure™ is a research-use-only blood-based test for monitoring solid organ transplantation.

How does Oncocyte support its operations financially?

Oncocyte is supported by strong core investors and has raised funds through private placement offerings, including a recent $15.8 million offering.

Where can I find more information about Oncocyte Corporation?

More information can be found on their official website at www.oncocyte.com.
Oncocyte Corporation

Nasdaq:OCX

OCX Rankings

OCX Stock Data

34.92M
13.38M
20.42%
50.6%
1.78%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
IRVINE